{
  "docId": "019de076-b279-75da-94b2-8ad8944b7652",
  "docSlug": "3080df08d7a75d95f523d4df26f037ae",
  "documentTitle": "Matinas BioPharma | Investor Presentation Deck | 29 slides",
  "authorId": "matinas-biopharma",
  "authorName": "Matinas BioPharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 29,
  "pageCount": 29,
  "prevPage": 28,
  "nextPage": null,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "overcrowded",
  "nDataPoints": 1,
  "notes": "The slide combines a financial summary with a timeline of milestones and a value proposition for their lead asset.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de076-b279-75da-94b2-8ad8944b7652/29",
  "deckHref": "/decks/019de076-b279-75da-94b2-8ad8944b7652",
  "deckJsonHref": "/decks/019de076-b279-75da-94b2-8ad8944b7652.json",
  "deckAnchorHref": "/decks/019de076-b279-75da-94b2-8ad8944b7652#slide-29",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.37,
        "y": 0.8
      },
      "kind": "list",
      "text": "Clinically Validated; Phase 3-ready asset; Highest unmet need",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4677e4a0-d93d-4371-8479-4576ce468ff5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.55,
        "x": 0.4,
        "y": 0.15
      },
      "kind": "list",
      "text": "Q1 - FDA Meeting to Finalize P3 Protocol; Q1 - LNC-docetaxel Safety Study; Q1 - Oral Delivery of Small Oligonucleotide; Q1 - MAT2203 Partnership; Q1 - Tumor Cell Line Screening; Q1 - LNC-docetaxel Tumor Models; Q2 - Platform Collaboration; 2024 - BARDA Funding",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "06c1d1de-0de6-4de4-a476-66a0c392a429",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.05,
        "y": 0.55
      },
      "kind": "metric",
      "text": "$18.2M in Cash, Cash Equivalents and Marketable Securities",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "178b7390-7e18-4539-beb8-1faf95194de5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.2,
        "x": 0.13,
        "y": 0.75
      },
      "kind": "paragraph",
      "text": "Non-Dilutive Financing Options",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4847f143-f4ce-4705-97fc-c67f2a1e7884",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.2,
        "x": 0.75,
        "y": 0.6
      },
      "kind": "paragraph",
      "text": "Substantial UPSIDE: LNCs Facilitating ORAL Delivery of Small Oligonucleotides And Establishing Internal and External Pipelines",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "79166cf7-0fc5-4af7-ae28-97598f7da28e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.2,
        "x": 0.13,
        "y": 0.4
      },
      "kind": "paragraph",
      "text": "Runway into Q3 2024",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bcf2a5ea-1e27-4b72-94ca-b8846133011d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.37,
        "y": 0.05
      },
      "kind": "title",
      "text": "Near-Term Milestones – Setup for Strong Start to 2024",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "265a4248-23da-49fd-aba0-67b76ac99b18",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.3,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "Matinas Investment Thesis",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7f093cee-1c2d-4c61-94cc-85a4bf2aa99a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "a17a58f8-46c6-482d-849e-a34d1455520e",
      "evidence": "Chronological list of milestones",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 29,
      "from": 26,
      "beatId": "38b7b373-3b8e-4b44-9aac-939eeb859d2a",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Impact & Next Steps",
      "beatSlug": "consultants-gambit-impact-next-steps",
      "evidence": "The document outlines recent key advances and near-term milestones",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}